Objectives: 1. Describe the reason why a specific MAP cutoff for starting vasopressors is not proscribed by sepsis guidelines 2. Recall five possible benefits of starting vasopressors early

Objectives: 1. Describe the criteria for using subcutaneous insulin instead of IV to treat DKA 2. Recall how to predict failure of transitioning from IV to subcutaneous insulin after DKA resolves View Previous View Next

Objectives: 1. Describe the risk and benefit being balanced when timing of anticoagulation after stroke is considered 2. Recall the evidence from randomized controlled trials on the safety of early DOAC use after stroke

Objectives: 1. Describe the necessary requirements in the 3 categories ASHP uses to qualify PGY-1 residency preceptors 2. Recall the most common and practical ways to meet the ASHP qualification requirements for preceptors

Objectives: 1. Describe the evidence supporting the major guideline recommendations for prolonged infusion beta lactams 2. Recall the real-world implications of guideline recommendations that are conditional and based on very low quality evidence

Objectives: 1. Describe the conflicting evidence behind the ROSE and ACURASYS trials 2. Recall the recommendations of the ESICM Guidelines on NMBA use as well as 3 potential legitimate use cases for NMBAs in ARDS

Objectives: 1. List the poisoning scenarios where lipid emulsion is unlikely to provide a benefit 2. Recall the poisoning scenarios when high dose insulin is first line therapy

Objectives: 1. Describe how the pharmacokinetics of azithromycin can support discontinuation before 5 days of therapy. 2. Recall the reasoning behind the IDSA CAP Guideline not recommending routine legionella urine antigen testing.

Objectives: 1. Recall the 4 types of immune mediated allergic reactions 2. Recall the purpose of implementing a screening tool from a stewardship point of view 3. Recall the differences between the 12 and 16 step desensitization protocols

Objectives: 1. Describe the randomized and retrospective trials that have evaluated half dose alteplase. 2. Recall the 3 major PE treatment guidelines and their position on half dose alteplase.

Objectives: 1. Describe the benefits and drawbacks of fixed dosing of 4-factor prothrombin complex concentrate for warfarin reversal. 2. Recall the major issues in fixed dosing of 4-FPCC that consensus must be reached on before a protocol can be finalized.

Objectives: 1. Describe the causes of iatrogenic hyperchloremia 2. Recall the evidence behind available prevention strategies for each possible cause of iatrogenic hyperchloremia